At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 266 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Relatlimab for Hepatocellular Carcinoma and 4 related conditions. Completed, enrolled 266 participants across 65 sites in 17 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
CountriesArgentina, Brazil, Chile, China, Czechia, France, Hong Kong, Japan, Mexico, New Zealand, Poland, Romania, Singapore, South Korea, Spain, Taiwan, Turkey (Türkiye)
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartFeb 2021
Primary CompletionAug 2023
Study CompletionNov 2025
TodayJul 2026
First PostedSep 28, 2020
Enrollment StartFeb 4, 2021
Primary CompletionAug 31, 2023
Study CompletionNov 19, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.8 years ago
Interventions
Nivolumabbiological
Specified dose on specified days
Relatlimabbiological
Specified dose on specified days